Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference15 articles.
1. Nicolas P. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00778-w
2. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3(Epub ahead of print).
3. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz HU. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30:233–56.
4. Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: regulatory considerations. Stat Med. 2000;19:2821–42.
5. Endrenyi L, Amidon GL, Midha KK, Skelly JP. Individual bioequivalence: attractive in principle, difficult in practice. Pharm Res. 1998;15:1321–5.